We compared 55 consecutive total hip replacements performed on 53 morbidly obese patients with osteoarthritis with a matched group of 55 total hip replacements in 53 nonobese patients. The groups were matched for age, gender, prosthesis type, laterality and pre-operative Harris Hip Score. They were followed prospectively for five years and the outcomes were assessed using the Harris Hip Score, the Short-form 36 score and radiological findings.
We compared 55 consecutive total hip replacements performed on 53 morbidly obese patients with osteoarthritis with a matched group of 55 total hip replacements in 53 nonobese patients. The groups were matched for age, gender, prosthesis type, laterality and pre-operative Harris Hip Score. They were followed prospectively for five years and the outcomes were assessed using the Harris Hip Score, the Short-form 36 score and radiological findings.
Survival at five years using revision surgery as an endpoint, was 90.9% (95% confidence interval 82.9 to 98.9) for the morbidly obese and 100% for the non-obese patients. The Harris Hip and the Short-form 36 scores were significantly better in the non-obese group (p < 0.001). The morbidly obese patients had a higher rate of complications (22% vs 5%, p = 0.012), which included dislocation and both superficial and deep infection.
In light of these inferior results, morbidly obese patients should be advised to lose weight before undergoing a total hip replacement, and counselled regarding the complications. Despite these poorer results, however, the patients have improved function and quality of life.
The body mass index (BMI) is calculated by dividing the subject's weight in kilograms by their height in metres squared. Obesity is defined as a BMI > 30 kg/m². 1 Morbid obesity is defined by National Institute for Clinical Excellence as a BMI > 40 kg/m² or > 35 kg/m² with at least one serious comorbidity. 2 The prevalence of obesity in the United Kingdom rose between 1993 and 2006 from 16% to 24% in women and from 13% to 24% in men. 3 A high BMI in early adult life is associated with an increased incidence of osteoarthritis of the hip. 4, 5 It is not surprising, therefore, that orthopaedic surgeons are seeing increasing numbers of morbidly obese patients who require total hip replacement (THR).
It is often suggested that morbid obesity prejudices the outcome of THR. Charnley 6 stated that THR surgery is contraindicated in obese patients. Obesity is associated with higher anaesthetic risk and operative complications after THR. In addition, there is a greater risk of serious cardiovascular and respiratory events, which can lead to increased post-operative morbidity. 7, 8 Other studies have demonstrated an increased risk of venous thromboembolic disease following joint replacement surgery in obese patients. 9, 10 Furthermore, obesity has a bearing on health economics, with obese patients staying in hospital longer than the general population.
11
There is a trend for orthopaedic surgeons to refuse a patient surgery until a target amount of weight loss is achieved. Recently, there has been a proposal by a health authority in England that funding for hip replacement be withheld in patients whose BMI is > 30 because of poor control of health costs. 4, 12 There is more recent evidence that obesity is associated with a higher complication rate following THR due to post-operative infection, dislocation and poorer functional outcome. 11, [13] [14] [15] [16] Other studies have shown that obese patients were found to do no worse than non-obese patients following this procedure. 12, [17] [18] [19] [20] [21] [22] A recent multicentre trial conducted in the United Kingdom, comparing THR in the non-obese and morbidly obese, concluded that all patients appear to gain similar benefits from surgery irrespective of their BMI. 17 However, the morbidly obese have always formed a small percentage in the few series where patients were assessed prospectively. 15, [17] [18] [19] [20] They may, however, require hip replacement at a younger age than those with a normal BMI. 23 In order to clarify this ongoing dilemma we designed a prospective, matched case-control study to assess the influence of morbid obesity on the outcome after THR in patients with osteoarthritis, with the aims of comparing the clinical, functional and quality of life outcomes following THR in a consecutive series of morbidly obese patients with a matched group of non-obese patients (BMI < 30 kg/m² with no comorbidities).
Patients and Methods
Between 1998 and 2003, 1636 THRs were performed in our unit by eight consultant orthopaedic surgeons. Patients were assessed pre-operatively by an independent audit nurse, who carried out a Harris Hip score (HHS) 24 and the Short-form (SF)-36 25 score on each patient. Two types of cemented femoral component were used: the Charnley primary THR (De Puy International, Leeds, United Kingdom) and the Lubinus SPII (Waldemar-Link GmbH, Hamburg, Germany). Each Charnley component had a 22.225 mm femoral head and each Lubinus one of 32 mm. All acetabular components were cemented Charnley allpolyethylene components. A standard anterolateral approach was used by all eight surgeons. Thromboprophylaxis with low molecular weight heparin was used in all patients. A routine post-operative rehabilitation programme, based on an integrated care pathway, was used. Independent prospective follow-up was undertaken by a dedicated audit team consisting of two specialist nurses. All patients were followed up at six, 18, 36 and 60 months.
During this time, THRs were performed for osteoarthritis in 75 morbidly obese patients (BMI > 40 or BMI > 35 with at least one serious comorbidity). Comorbidities included hypertension, cardiovascular disease, diabetes, cancer, previous deep-vein thrombosis or pulmonary embolus. Nine patients (10 hips) were excluded because of incomplete follow-up, a further three were lost to follow-up and ten (11 hips) had died. There remained 53 morbidlyobese patients (55 hips) who were included in the final analysis. These patients were individually matched with a control group of 53 non-obese patients (55 hips) who were followed up for five years.
The two groups were matched for age, gender, type of prosthesis, laterality (right or left, unilateral or bilateral) and pre-operative HHS. It was not always possible to identify a non-obese patient with exactly the same pre-operative HHS as a morbidly obese patient. In this instance, the control with the next 'worst' score was identified. If no other control with a 'worse' score could be identified, the control with the next 'better' score was used. This protocol was maintained for matching all the patients so that the control group would have either a similar, or a worse, pre-operative HHS than the morbidly obese patients. Patients were matched using the pre-operative data in isolation and without knowing the individual outcomes. The HHS and SF-36 scores were used to assess post-operative function and quality of life. 25 Survival at five years was defined by using revision as the endpoint. We performed a power calculation on the basis that we wanted to detect a medium-sized effect as defined by Cohen (p = 0.3), using failure by revision as the primary outcome. 26 Assuming an α error = 0.05, power 80% to detect a significant difference, and an allocation ratio of 1:1 as it was a matched study, a sample size of 102 (51 in each group) would be required. All complications were noted. Superficial infection was defined as a wound infection that resolved with oral antibiotics, whereas deep infection required re-operation or revision. Deep-vein thrombosis was confirmed by venography or duplex ultrasound scanning. A pulmonary embolus was confirmed by CT pulmonary angiography. The operation times and the number of dislocations were also noted.
All radiographs were evaluated by a single observer (BMS) at five years using the DeLee/Charnley and Gruen systems. 27, 28 The DeLee and Charnley system identifies radiolucency in three acetabular zones. Gruen identifies seven femoral zones on the anteroposterior radiograph. Statistical analysis. This was undertaken using SPSS v13.0 (SPSS Inc., Chicago, Illinois). A p-value of < 0.05 was considered significant. Scoring of the SF-36 was carried out according to the coding and formulae detailed in the United Kingdom SF-36 analysis and interpretation manual. 29 Survival analysis was calculated using the Kaplan-Meier method, with revision as an endpoint. The two groups were compared using Student's t-test or the Mann-Whitney U test for continuous data and the chi-squared test for categorical data.
Results
There was no significant difference between the demography of the two matched groups except for the BMI (Table I) . In both groups, the post-operative HHS at six months was significantly better than the pre-operative score (p < 0.001). This was still true at five years (p < 0.001). There was no significant improvement in the HSS in either group after six months (p > 0.05). The HHS at five years was significantly better in the non-obese group than in the morbidly obese group (91.8 vs 85.4, p < 0.001) but not significant between their mean improvement after five years (52.0 vs 48.1, p = 0.825). This difference became apparent from 18 months (91.0 vs 85.0, p = 0.01 at 18 months; 92.1 vs 85.5, p < 0.001 at 36 months). The HHS for both groups are shown in Figure 1 .
The mean pre-operative SF-36 scores were significantly poorer in two of the eight dimensions in the morbidly obese group (pain, p = 0.017, physical functioning, p = 0.42). In both groups the mean scores of all the dimensions except mental health and general health perception improved significantly following THR, and remained so throughout the follow-up period compared to the pre-operative scores (p < 0.001). The greatest change in SF-36 scores occurred between the pre-operative assessment and the six-month review. At the five-year follow-up the mean scores for physical functioning and energy/vitality were significantly poorer in the morbidly obese group (p < 0.001, p = 0.20, respectively).
At five years, peri-acetabular radiolucency was seen in 69% (n = 38) of non-obese and 51% (n = 28) of morbidly obese patients (p = 0.051), with 29% (n = 16) of the nonobese and 11% (n = 6) of the morbidly obese having lucency in two or more zones (p = 0.02). Femoral radiolucency was seen in 84% (n = 46) of non-obese and 76% (n = 42) of morbidly obese patients (p = 0.34), with 33% (n = 18) of the non-obese and 20% (n = 11) of the morbidly obese having lucency in four or more zones (p = 0.13).
The complication rates were higher in the morbidly obese group (22% vs 5%; p = 0.012, Table II ). There were two deep and seven superficial infections in these patients compared with two superficial and no deep infections in the nonobese group. There was one pulmonary embolus in the morbidly obese group. There were three dislocations in the morbidly obese group and one in the non-obese. All three in the morbidly obese group required a revision procedure; one hip dislocated three times in the first two weeks requiring a Charnley augmented acetabular component at revision, another dislocated at both ten and 16 months requiring revision with an augmented component and the third involved three dislocations of one hip in the first week following a bilateral THR. An open reduction was required at the last dislocation and an augmented component inserted. This patient developed deep infection requiring a two-stage revision with a poor outcome, being confined to a wheelchair. All obese patients whose hips dislocated had similar standard-sized Lubinus femoral components and 32 mm heads. There were components of smaller outer diameter in two and one was larger. The non-obese patient who dislocated had a standard size Lubinus component with a 32 mm head and a small outer diameter component. None of these hips had any documented reduction in their offsets or mention of malpositioning in their primary operation. A summary of the failures is presented in Table III . The five-year survival, using revision surgery as an endpoint, was 90.9% (95% CI 82.9 to 98.9) for the morbidly obese and 100% for the non-obese patients. The mean operating time for nonobese patients was 89 minutes (64 to 105) and for the morbidly obese patients was 97 minutes (68 to 125; p = 0.187).
Discussion
Increasing numbers of patients awaiting THR are overweight and most have at least one significant comorbidity. In one series, about half of the patients were classified as obese based on their BMI. 19 A strong association has been found between rising BMI and the need for total knee and hip replacement. 30, 31 The health risks to obese individuals include coronary heart disease, hypertension, diabetes, cancer and death from any cause. It is difficult to predict how these translate into surgical risks. There have been conflicting data in orthopaedic patients. 32 Obese patients have been shown to have higher pulmonary risks attributed to decreased chest wall compliance and decreased functional residual capacity. 33, 34 Søballe et al 18 showed that the operative time and hospitalisation were not increased in obese patients, but they observed greater peri-operative blood loss.
Our study showed that following THR, morbidly obese patients were more likely to suffer significant complications, but this was not found or highlighted in some previous studies. 12, 15, 17, 21, 35 This may be because we only included morbidly obese patients in our study. Both the morbidly obese patients who developed deep infection underwent revision surgery. All three morbidly obese patients with post-operative dislocation failed to respond to more conservative treatment, such as a closed reduction and required revision. We consider that this may be due to malalignment of the acetabular component due to difficulty in exposing and accessing the acetabulum in the morbidly obese, although we were not able to quantify the degree of malpositioning in these patients radiologically or during the subsequent revision operation. Apart from the patient left in a wheelchair with ongoing deep infection, the others recovered well following their revision.
In a previous study it was found that obesity substantially increased the rate of infection after primary THR in women, but not in men. 12 This may be due to the different body habitus of men and women. In obese men most of the excess weight is around the waist and not around the hips, whereas in women it is around the hips, making surgery more difficult and prolonged. Most of the patients in the morbidly obese group in our study were women, which could therefore explain this higher complication rate.
A recent study 36 found no strong link between high BMI and the radiological severity of osteoarthritis of the hip, but the authors did find a significantly poorer outcome in terms of pain and functional disability as measured by the HHS in those with increasing BMI. Our study did not show any significant difference in the rate of peri-acetabular or femoral radiolucency in both groups at five years. Surprisingly, the morbidly obese patients had significantly less peri-acetabular radiolucency at five years. This could reflect the fact that nonobese patients are more mobile and hence likely to increase acetabular wear. In addition, we found no significant difference between the mean operating times in the two groups.
The SF-36 scores give an accurate reflection of function in patients following THR. In a study on the relationship between quality of life after THR and obesity by Chan and Villar, 19 it was found that there was no statistically significant difference between non-obese, mildly obese and moderately obese patients at one and three years' in terms of the improvement in quality of life. Another study 37 concluded that obese patients enjoyed as much improvement and satisfaction as other patients from total joint replacement. The results in both our patient groups showed that postoperative improvement in the SF-36 score was greatest at six months and that this was maintained for up to five years. This, together with the improvement in the HHS, showed a significant gain in the quality of life which lasted for five years, irrespective of the BMI. This is comparable to an earlier study in our department on the quality of life and functional outcome after THR. 38 The strengths of our study are that it was a comparison matched investigation with controls, HHS, SF-36, complete radiological grading at five years with prospectively acquired data and full follow-up. Statistical analysis was performed and survival data are presented. This study is the first to use BMI > 35 with associated significant comorbidity to define morbid obesity, as recommended by NICE. 2 This is a more accurate definition, as it highlights the common association of high BMI with significant underlying medical conditions such as hypertension, diabetes and cardiovascular disease, which more closely reflects the patients requiring hip joint replacement.
The limitations of the study are that it was based in a single institution with fewer morbidly obese patients to recruit into a matched cohort. The implant and surgeon demographics were not homogeneous, which probably reflects current practice in most district general hospitals in the United Kingdom. We accept that radiological outcomes were judged by a single observer, and no intra-observer variability tests were carried out. Even though the choice of implant, stem and the size of the component were not standardised in our series, we have attempted to reduce these confounding factors by matching the corresponding type of femoral component in each group. Despite being the implant used more commonly in our series, we are unable to conclude that the Lubinus femoral component is the most appropriate choice in obese patients. We were unable to measure the degree of acetabular malpositioning accurately prior to revision surgery in the obese patients who had dislocated and cannot fully assume that malpositioning is entirely caused by difficulty in access owing to the obesity.
Some recently published results on obesity and surgery support THR in the morbidly obese [17] [18] [19] [20] [21] and some do not. 11, 13, 15, 16 The operating surgeon now has conflicting data to analyse before counselling patients as to the risks and benefits of THR surgery. We have shown that morbidly obese patients do have a higher risk of post-operative complications, including poorer function. Because obesity is potentially treatable, we should advise our morbidly obese patients who are candidates for THR of their significantly higher complication rate (p = 0.012), which they should be able to reduce by losing weight.
In this matched study we found that THR in the morbidly obese was associated with higher complication rates, poorer clinical outcome scores and inferior five-year survival, yet there is an improvement in the quality of life. Such patients should be made aware of the increased risks, associated complications and inferior clinical outcome following this operation. Randomised controlled trials with longer-term follow-up will be required to report on outcomes in the morbidly obese following THR.
